122 related articles for article (PubMed ID: 36453625)
1. Disparities in Access to Hepatitis C Treatment Among Arizona Medicaid Beneficiaries With Chronic Hepatitis C.
Jiang X; Song HJ; Chang CY; Wilson D; Guo J; Lo-Ciganic WH; Park H
Med Care; 2023 Feb; 61(2):81-86. PubMed ID: 36453625
[TBL] [Abstract][Full Text] [Related]
2. Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?
Jain MK; Thamer M; Therapondos G; Shiffman ML; Kshirsagar O; Clark C; Wong RJ
Hepatology; 2019 Jan; 69(1):51-63. PubMed ID: 30019478
[TBL] [Abstract][Full Text] [Related]
3. Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016.
Jung J; Du P; Feldman R; Kong L; Riley T
J Manag Care Spec Pharm; 2019 Nov; 25(11):1236-1242. PubMed ID: 31663464
[TBL] [Abstract][Full Text] [Related]
4. Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population.
Marcus JL; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Lam JO; Pauly MP; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ
Public Health Rep; 2018; 133(4):452-460. PubMed ID: 29750893
[TBL] [Abstract][Full Text] [Related]
5. Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C.
Park H; Song HJ; Jiang X; Henry L; Cook RL; Nelson DR
Hepatol Commun; 2021 Feb; 5(2):203-216. PubMed ID: 33553969
[TBL] [Abstract][Full Text] [Related]
6. Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020.
Thompson WW; Symum H; Sandul A; ; Gupta N; Patel P; Nelson N; Mermin J; Wester C
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(32):1011-1017. PubMed ID: 35951484
[TBL] [Abstract][Full Text] [Related]
7. Impact of Direct-acting Antivirals on Hepatocellular Carcinoma and Mortality Among Medicaid Beneficiaries With Hepatitis C.
Jiang X; Song HJ; Chang CY; Wilson DL; Lo-Ciganic WH; Park H
Med Care; 2023 Aug; 61(8):505-513. PubMed ID: 37223993
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C Treatment Initiation Among US Medicaid Enrollees.
Kapadia SN; Zhang H; Gonzalez CJ; Sen B; Franco R; Hutchings K; Wethington E; Talal A; Lloyd A; Dharia A; Wells M; Bao Y; Shapiro MF
JAMA Netw Open; 2023 Aug; 6(8):e2327326. PubMed ID: 37540513
[TBL] [Abstract][Full Text] [Related]
9. Changes in Use of Hepatitis C Direct-Acting Antivirals After Access Restrictions Were Eased by State Medicaid Programs.
Davey S; Costello K; Russo M; Davies S; Lalani HS; Kesselheim AS; Rome BN
JAMA Health Forum; 2024 Apr; 5(4):e240302. PubMed ID: 38578628
[TBL] [Abstract][Full Text] [Related]
10. Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection.
van Boemmel-Wegmann S; Lo Re V; Park H
Dig Dis Sci; 2020 Nov; 65(11):3159-3174. PubMed ID: 31938995
[TBL] [Abstract][Full Text] [Related]
11. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
[No Abstract] [Full Text] [Related]
12. Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist.
Nephew LD; Wang Y; Mohamed K; Nichols D; Rawl SM; Orman E; Desai AP; Patidar KR; Ghabril M; Chalasani N; Kasting ML
J Viral Hepat; 2022 May; 29(5):366-374. PubMed ID: 35254695
[TBL] [Abstract][Full Text] [Related]
13. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.
Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
J Clin Gastroenterol; 2018 Aug; 52(7):641-647. PubMed ID: 28590325
[TBL] [Abstract][Full Text] [Related]
14. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.
Pham TT; Keast SL; Farmer KC; Thompson DM; Rathbun RC; Nesser NJ; Holderread BP; Skrepnek GH
J Manag Care Spec Pharm; 2018 Jul; 24(7):664-676. PubMed ID: 29952711
[TBL] [Abstract][Full Text] [Related]
15. Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C.
Kalidindi Y; Jung J; Feldman R; Riley T
JAMA Netw Open; 2020 Jul; 3(7):e2011055. PubMed ID: 32692371
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States.
Nguyen VH; Kam L; Yeo YH; Huang DQ; Henry L; Cheung R; Nguyen MH
JAMA Netw Open; 2022 Dec; 5(12):e2245424. PubMed ID: 36477481
[TBL] [Abstract][Full Text] [Related]
17. Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents?
Du P; Wang X; Kong L; Jung J
Telemed J E Health; 2021 May; 27(5):488-494. PubMed ID: 32882154
[No Abstract] [Full Text] [Related]
18. Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis.
Herink MC; Geddes J; Vo K; Zaman A; Hartung DM
J Manag Care Spec Pharm; 2021 Jul; 27(7):856-864. PubMed ID: 34185560
[No Abstract] [Full Text] [Related]
19. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders.
Jiang X; Song HJ; Wang W; Henry L; Childs-Kean LM; Re VL; Park H
J Manag Care Spec Pharm; 2021 Jul; 27(7):873-881. PubMed ID: 34185563
[No Abstract] [Full Text] [Related]
20. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]